Education
About Us
Working with TipRanks
Follow Us
Opus Genetics, Inc. (IRD)
NASDAQ:IRD
IRD Stock Chart & Stats
$4.25
$0.08(5.63%)
At close: 4:00 PM EST
$4.25
$0.08(5.63%)
Day’s Range― - ―
52-Week Range$0.65 - $4.49
Previous CloseN/A
Volume154.21K
Average Volume (3M)1.07M
Market Cap
$293.10M
Enterprise Value$263.35M
Total Cash (Recent Filing)$30.82M
Total Debt (Recent Filing)$1.07M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
May 08, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding68,964,210
10 Day Avg. Volume983,924
30 Day Avg. Volume1,074,031
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.73
Price to Sales (P/S)2.89
P/FCF Ratio-1.24
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue18.00
Enterprise Value/Gross Profit321.16
Enterprise Value/Ebitda-6.11
Forecast
1Y Price Target
$8.86Price Target Upside108.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$16.25M
Bulls Say, Bears Say
Bulls Say
Early Efficacy And Biological ActivityEye imaging showed resolution of retinal fluid and structural improvement in the vision-related central retina that coincided with measurable vision gains, supporting on-target biological activity.
Regulatory And Commercial ProgressRegulatory acceptance of a supplemental application for a marketed eye drop and a U.S. commercialization agreement with a large partner provide a pathway to milestone payments and royalties, strengthening commercial prospects.
Safety ProfileEarly clinical data indicate a clean ocular safety profile with no treatment-related inflammation or serious adverse events, supporting continued dosing and clinical advancement.
Bears Say
Funding And Cash Runway RiskLimited cash relative to current spending creates the risk that additional financing may be required, which could dilute shareholders and delay program execution.
Potential Analyst Conflict Of InterestAnalyst disclosures of business relationships with covered companies raise concerns about potential conflicts of interest that could bias published assessments.
Small Sample And Data UncertaintyFindings are based on a single sentinel participant and a very small treated patient group, creating significant uncertainty about how results will generalize across a larger patient population.
Opus Genetics News
IRD FAQ
What was Opus Genetics, Inc.’s price range in the past 12 months?
Opus Genetics, Inc. lowest stock price was $0.65 and its highest was $4.49 in the past 12 months.
What is Opus Genetics, Inc.’s market cap?
Opus Genetics, Inc.’s market cap is $293.10M.
When is Opus Genetics, Inc.’s upcoming earnings report date?
Opus Genetics, Inc.’s upcoming earnings report date is May 08, 2026 which is in 65 days.
How were Opus Genetics, Inc.’s earnings last quarter?
Opus Genetics, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.12.
Is Opus Genetics, Inc. overvalued?
According to Wall Street analysts Opus Genetics, Inc.’s price is currently Undervalued.
Does Opus Genetics, Inc. pay dividends?
Opus Genetics, Inc. does not currently pay dividends.
What is Opus Genetics, Inc.’s EPS estimate?
Opus Genetics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Opus Genetics, Inc. have?
Opus Genetics, Inc. has 68,964,210 shares outstanding.
What happened to Opus Genetics, Inc.’s price movement after its last earnings report?
Opus Genetics, Inc. reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -2.538%.
Which hedge fund is a major shareholder of Opus Genetics, Inc.?
Currently, no hedge funds are holding shares in IRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opus Genetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.86 (108.47% Upside)
$8.86 (108.47% Upside)
Blogger Sentiment
Bullish
IRD Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $8.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
337.69%
12-Months-Change
Fundamentals
Return on Equity
-338.75%
Trailing 12-Months
Asset Growth
-10.56%
Trailing 12-Months
Company Description
Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
IRD Stock 12 Month Forecast
Average Price Target
$8.86
▲(108.47% Upside)
Technical Analysis
Ownership Overview
19.45% Insiders
2.24% Mutual Funds
17.17% Other Institutional Investors
58.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---